🏅 FDA Orphan Designation
Qutenza
capsaicin
Manufacturer: Averitas Pharma, Inc.
Indicated for:
FDA-Approved Indications (1)
NON RARE IN EUROPE: Post-herpetic neuralgiaOrphan Designation
Management of neuropathic pain associated with postherpetic neuralgia
Indications & Usage
1 INDICATIONS AND USAGE QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. QUTENZA is a TRPV1 channel agonist indicated for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. ( 1 )
💙 Support Programs
View all →Qutenza
Averitas
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.